Navigation Links
Mayo Clinic researchers challenge sepsis theory

United States, half of which are fatal. Sepsis is the second most common cause for admissions to critical care units and can be a significant complication of some heart surgeries. The Mayo Clinic researchers believe current sepsis treatment isn't more effective because the theory of sepsis is too narrow. Current treatments don't target all causes of sepsis syndrome -- only the bacterial poison cause -- which was described by a 19th century researcher as "the putrid gift."

"Our work is the first to show that this change in receptors in the body is the first true step in the sepsis syndrome, rather than the introduction of a poison," explains Dr. Platt. "The importance then becomes clear. If we really do now have the first cause of sepsis -- not the bacteria, but the unconstrained receptors -- then we can therapeutically interfere with that receptor release mechanism by designing new treatments and possibly, and at long last, develop drugs that treat all cases of sepsis."

Challenging Existing Theories

Dr. Platt and his colleague, Gregory Brunn, Ph.D., say the evidence they've published compels this conceptual shift about sepsis. "The problem with the concept of sepsis, and what provoked some of our interest, is that it has been known for 10 years that when you treat with anything that interrupts bacterial poisons, it has no impact on the septic disease. That suggests that perhaps the poisons don't cause sepsis after all," Dr. Platt says. "Problems such as this caused us to ask, 'Could there be something else driving sepsis, other than the classic poisoning explanation?'"

Mayo Discovers Key Piece of the Puzzle

Dr. Platt and colleagues discovered several years ago that certain naturally-occurring molecules can stimulate receptors once thought to be exclusive for the bacterial poisons (endotoxins). Once stimulated, the receptors (toll-like receptors) set the sepsis cycle into motion. "This finding was very exciting,"
'"/>

Source:Mayo Clinic


Page: 1 2 3

Related biology news :

1. Mayo Clinic Researchers Create Obedient Virus; First Step To Use Measles Virus Against Cancer
2. Chronic Sinus Infection Thought To Be Tissue Issue, Mayo Clinic Scientists Show Its Snot
3. Clinical trial to test stem cell approach for children with brain injury
4. Mayo Clinic collaboration discovers protein amplifies DNA injury signals
5. Mayo Clinic researchers discover cancer cells may move via wave stimulation
6. Mayo Clinic study finds two genes predict outcome for breast cancer patients
7. Mayo Clinic Cancer Center: Harnessing the measles virus to attack cancer
8. Mayo Clinic collaboration mining of ancient herbal text leads to potential new anti-bacterial drug
9. Mayo Clinic study suggests that a central nervous system viral infection can lead to memory deficits
10. Mayo Clinic: Gene expression profiling not quite perfected in predicting lung cancer prognosis
11. NYU researchers simulate molecular biological clock
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Mayo Clinic researchers challenge sepsis theory

(Date:2/12/2015)...   MedNet Solutions , a global life ... systems, has recently bolstered its iMedNet™ ... iMedNet as the eClinical solution of ... consultants.  Building on the Program,s existing benefits (including ... co-marketing opportunities), MedNet,s new and improved program provides ...
(Date:2/10/2015)...  Alere Inc. (NYSE: ALR), a global leader ... the quarter ended December 31, 2014. ... Alere said, "We made substantial progress in the ... leader in rapid diagnostics and delivering against our ... in early January enabled us to substantially reduce ...
(Date:2/5/2015)... PARK, N.C. , Feb. 5, 2015  Marken ... specialist logistics company and has launched a new marketing ... Clinical Logistics Organization (CLO).  The new campaign focuses on ... on patient, protocol and shipments. The first ... , aligns Marken,s priorities with its client,s priorities. ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35
... This press release is available in Spanish . ... brown marmorated stink bug (BMSB) is now in at least 39 ... major economic threat to orchard fruits, garden vegetables and row crops. ... pest as its top "invasive insect of interest." But ...
... Irvine, Calif., Jan. 7, 2013 Halting climate change will ... system" to eradicate harmful carbon dioxide emissions, not just stabilize ... scientists. In a Jan. 9 paper in Environmental ... and others take a fresh look at the popular "wedge" ...
... immigrants from Italy and their offspring form one of the ... on their state of health and risk of mortality. In ... the University of Zurich,s Institute of Social and Preventative Medicine ... background. Immigrants from Italy live longer ...
Cached Biology News:Combating USDA's top-ranked invasive insect 2Major cuts to surging CO2 emissions are needed now, not down the road, study finds 2Italian immigrants live longer 2
(Date:2/27/2015)... 2015 A paper published today, " ... " in Science Translational Medicine, demonstrates ... reduce the risk associated with investing in the ... levels of funding for developing so-called "orphan" drugs. ... collaboration between scientists at the National Center for ...
(Date:2/27/2015)... SAN DIEGO , Feb. 27, 2015  Pfenex ... in the development of biosimilar therapeutics, today announced that ... San Francisco Marriott Marquis on March 2 nd ... will participate on a panel discussing the current state ... World of Biosimilars . For more ...
(Date:2/26/2015)... NEW YORK , Feb. 26, 2015 ... commenced Factual Stock Report coverage on MabVax Therapeutics ... Inc. (MBVX) is a clinical stage biotechnology company focused ... address unmet medical needs in the treatment of cancer. ... products based on the protective immune responses generated by ...
(Date:2/26/2015)... , Feb. 26, 2015   Regulus Therapeutics Inc ... leading the discovery and development of innovative medicines targeting ... Ph.D., President and Chief Executive Officer of Regulus, will ... 35 th Annual Healthcare Conference on Wednesday, March ... being held at the Boston Marriott Copley Place.  ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3
... EVANSTON, Ill. --- Carbon nanotubes are promising materials ... mechanical, thermal, chemical, optical and electrical properties. , ... nanotubes to make thin films that are semitransparent, ... of colors, with an appearance similar to stained ...
... April 9 Baxter Healthcare Corporation,today announced ... coating, the first needleless intravenous (IV) connector ... for hospitals in the,United States and Canada. ... kill on,average 99.9 percent or more of ...
... discussed during Omnicell,educational, programs April 15 at ... The Mid-America Club in Chicago, MOUNTAIN ... Inc. (Nasdaq: OMCL ), a leading provider,of ... in,healthcare facilities, and Rice Memorial Hospital today announced ...
Cached Biology Technology:Carbon nanotubes made into conductive, flexible 'stained glass' 2Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 2Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 3Baxter's V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals 4Rice Memorial Hospital Implements SinglePointe(TM) Automated Patient-Specific Management Solution From Omnicell 2Rice Memorial Hospital Implements SinglePointe(TM) Automated Patient-Specific Management Solution From Omnicell 3
... PBL's bioassays for interferons are cytopathic effect inhibition ... Sample types include; tissue culture supernatents; serum ... these assays, one unit is defined as the ... the cytopathic effect of viral infection by 50%. ...
Request Info...
...
... is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
Biology Products: